Elevated IL-6 and FGF-23 levels predicted left ventricular hypertrophy (AUC 0.768 for IL-6) and heart failure risk (AUC 0.758 for FGF-23) in patients with diabetes mellitus.
Observational (n=320)
Do biomarkers such as IL-6 and FGF-23 predict left ventricular hypertrophy and heart failure risk in patients with diabetes mellitus?
IL-6 and FGF-23 show acceptable discrimination as early biomarkers for left ventricular remodeling and heart failure risk in patients with diabetes mellitus.
Effect estimate: AUC 0.768
p-value: p=<0.001
Objective: Diabetes mellitus (DM) is associated with increased cardiovascular mortality. The aim of this study was to identify early biomarkers of cardiovascular risk in DM patients, focusing on left ventricular hypertrophy (LVH) and heart failure (HF) risk. Design and method: The study included 255 DM patients aged 34 to 75 years and 65 controls without DM. All patients underwent standard clinical and laboratory examination, with an assessment of the levels of VEGF-A, FGF-23, RANTES, TNF-alpha, MIG, CRP/hsCRP, IL-6, podocin, KIM-1, homocysteine, serum creatinine, GFR and albumin/creatinine ratio (A/C). An echocardiographic investigation was performed to study structural and geometric heart parameters. LVH was diagnosed when the left ventricular myocardial mass index (LVMI) exceeded 115 g/m2 in men and 95 g/m2 in women. DM patients were stratified by LVH (LVH+, n=103; LVH-, n=152). LVH+ patients were further stratified by HF risk using guideline thresholds (BNP >35 pg/mL and/or NT-proBNP >125 ng/mL): HF+, n=72; HF-, n=31. Results: Compared with controls, DM patients had higher BNP, NT-proBNP, LV mass and LVMI (p0.05). Within LVH+ patients, in comparison with the HF- group, HF+ subjects had higher VEGF-A (p=0.004), FGF-23 (3.22 1.09; 9.55 vs 0.52 0.27; 1.08 pmol/L; p0.9 mg/ml; Se 73%, Sp 68%). For HF risk, FGF-23 (AUC=0.758; cut-off >0.9 pmol/L; Se 73.0%, Sp 68.2%) and IL=6 (AUC=0.749; cut-off >2.13 mg/ml; Se 68.2%, Sp 67.4%) were predictive markers. Conclusions: IL-6 and FGF-23 are associated with LV remodeling and HF risk in DM, showing acceptable discrimination for early risk stratification.
Vasilkova et al. (Fri,) conducted a observational in Diabetes mellitus (n=320). IL-6 and FGF-23 vs. Controls without diabetes or lower biomarker levels was evaluated on Left ventricular hypertrophy and heart failure risk (AUC 0.768, p=<0.001). Elevated IL-6 and FGF-23 levels predicted left ventricular hypertrophy (AUC 0.768 for IL-6) and heart failure risk (AUC 0.758 for FGF-23) in patients with diabetes mellitus.